...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
...
6/21/2024: Release v1.43.1
Meningococcal B Update
- Updated ICE to support CVX 316 (Meningococcal MenABCWY (Penbraya)) in the Meningococcal B Vaccine Group.
- Addressed an issue in the Meningococcal B Vaccine Group - Series Selection Rules that resulted in (under certain circumstances) the incorrect series being selected.
Meningococcal ACWY Update
- Updated ICE to support CVX 316 (Meningococcal MenABCWY (Penbraya)) in the Meningococcal ACWY Vaccine Group.
DTP Update
- Added recommendation reason codes ADMINISTER_TDAP_OR_TD and SUPPLEMENTAL_TEXT, descriptive Text: "Administer either Tdap or Td" associated with the vaccine group-level recommendation for the recurring booster dose. Given the recurring booster dose recommendation is at the vaccine group level (DTP), this additional information helps clarify the recommendation.
Influenza Update
- Added support for CVX 320, Influenza, MDCK, trivalent, preservative.
MMR Update
- Addressed an issue where ICE was not counting a reported indication of immunity when a patient receives one dose of MMR followed by antigens.
Varicella Update
- Addressed an issue where ICE was not returning the correct forecast if 2 or more proof of immunity or 2 or more diseases were documented.
Hep A / Hep B Update
- Addressed an issue where ICE was not returning the correct forecast if 2 or more proof of immunity were documented.
Doses Remaining Output
- Added a configurable setting for the optional Series Selection and Number of Doses Remaining feature. The setting allows for an ICE service provider to indicate, for each vaccine group, the return of dose number in the series or the dose count in the vaccine group.
3/18/2024: Release v1.42.1.4
...
11/03/2023: Release v1.41.1
Pneumococcal
- Added support for PCV20 (CVX 216) use in children, with the following changes in the Pneumococcal Child Series:
- Lowered the absolute minimum age of CVX 216 from 18 years - 4 days to 6 weeks - 4 days.
- Incorporated CVX 216 as a valid CVX code per dose.
- The CVX 216 changes are in the Pneumococcal Child Series only. In a future release, HLN will refine the logic for handling of CVX 216 administered between the ages of 6 and 19 years when intended for the adult series.
Note: There are no changes to the ICE Implementation Guide.
...
- Updated the live vaccine interval rule to allow for an absolute minimum interval of 24 days, instead of 28 days, for live virus vaccines from the same vaccine group. Note, this is relevant for the following vaccine groups: H1N1, Influenza, MMR, Varicella, Zoster.
DTP
- Updated the "Rules for Recommending at the CVX Code vs. Vaccine Group Level Within the Primary Series"
- Added support for vaccines CVX 196 and CVX 195.
Influenza
- Updated CVX names to better align with CDC CVX code descriptions.
- Minor rule edits to enhance rule clarity.
MMR
- Updated the dose 1 to dose 2 absolute minimum interval from 28 days to 24 days.
- Updated MMR deduplication/same day logic to evaluate an MMRV shot first, followed by MMR, then other MMR vaccine group vaccines, in accordance with the Two Shots, Same Vaccine Group, Same Day Exception Rules for MMR.
- Addressed an issue where ICE incorrectly indicated a single antigen or a double antigen vaccine as a valid dose of MMR for adults age 19 years and older.
Varicella
- Updated the dose 1 to dose 2 absolute minimum interval from 28 days to 24 days for patients >= 13 years of age.
8/21/2023: Release v1.39.2
...
- Updated wiki to reflect the 2023-2024 season. Note: there are no evaluation and forecasting changes for the 2023-2024 season.
- Added support for CVX 231 (Influenza, Southern Hemisphere, high-dose, quadrivalent). Note: this CVX does not count toward immunity.
Pneumococcal
- Fix to the Adult Recommendation Rules supplemental text descriptive text when a patient is >= 19 years and < 65 years of age and the series is not complete. The descriptive text now indicates patients who previously received a PCV13 should receive PCV20 or PPSV23 (previously only PPSV23 was noted).
3/17/2023: Release v1.38.1
...
- Added support for Novavax as a primary series option for ages 12 and older: new Novavax COVID-19 Series
- Added support for bivalent boosters for ages 5 and older
- Added support for Novavax monovalent booster for adults ages 18 and older
- Added support for new vaccines: CVX 229, CVX 300, and CVX 301
- Updated the Pfizer COVID-19 Series
- additional valid CVX codes per dose: CVX 300, CVX 301
- indication of an invalid CVX code per dose: CVX 229
- indication of a latest recommended interval for dose 1 to dose 2: 8 weeks
- additional series special rules
- Updated the Moderna COVID-19 Series
- additional series special rules
- Updated the Mixed Product COVID-19 Series
- additional valid CVX codes per dose: CVX 211, CVX 300, CVX 301
- indication of an invalid CVX code per dose: CVX 229
- additional series special rules
- removed Rule for CVX 218
- Updated General Rules
- Updated Series Completion Special Rules
- Moderna COVID-19 Series: Added logic based on execution date
- Pfizer COVID-19 Series or Mixed Product COVID-19 Series: Added logic based on execution date
- COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine: Added logic based on execution date
- Updated and added Booster Dose rules: Added recommendation and evaluation rules for third booster dose
- Updated and added Additional Dose rules
- Updated Series Completion Special Rules
...
- Added support for PCV15 as an option for pneumococcal conjugate vaccination of persons age <19 years
- Fixed bug that, in certain circumstances, recommended an extra PPSV23 after the series had already been completed at >= 65 years
8/31/2022: Release v1.36.1
...
- This release includes the following COVID-19 updates:
- Added additional support and logic in ICE to handle the following:
- Booster Dose Rules
- Updated booster dose recommended age to 12 years
- Updated booster dose recommended interval to 5 months after completion of mRNA vaccine primary series.
- Additional Dose Rules
- Added support for additional dose for immunocompromised persons aged 5+
- COVID-19 Vaccines Not Authorized by FDA Rules
- Updated rules for Novavax (CVX 211) COVID-19 vaccine now that WHO has approved it for use under their EUL
- Updated rules to accommodate the fact that patients who have not completed all recommended doses of a COVID-19 vaccine series not authorized by FDA, but approved by WHO, do not need to restart a primary vaccination series in the United States.
- Booster Dose Rules
- Added additional support and logic in ICE to handle the following:
...
- This release includes the following COVID-19 updates:
- Added additional support and logic in ICE to handle the following:
- COVID-19 Booster Dose rules - Updated and added additional rules for patients who completed Pfizer 2-dose series, Moderna 2-dose series, Janssen 1-dose series, Pfizer COVID-19 Child (5-17) 2-dose series, COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine.
- Booster Dose Minimum Age has been updated to 16 years to support new CDC recommendation that 16-17 year olds "may" receive a Pfizer booster.
- COVID-19 Additional Dose rules - Updated and added additional rules for patients who completed Pfizer 2-dose series, Moderna 2-dose series, Janssen 1-dose series, Pfizer COVID-19 Child (5-17) 2-dose series, COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine.
- New COVID-19 vaccine (CVX 217) - Added support and logic
- Note - CVX 217 is a new Pfizer formulation for ages 12+ under EUA; can be used in the same way as CVX 208
- Pfizer 2-dose series
- Updated Absolute Minimum Intervals between Dose 1 and Dose 2
- Moderna 2-dose series
- Updated Absolute Minimum Intervals between Dose 1 and Dose 2
- Updated Absolute Minimum Age for Dose 1
- Updated Absolute Minimum Age for Dose 2
- Updated Minimum Age for Dose 2
- Updated Routine Age for Dose 2
- COVID-19 Booster Dose rules - Updated and added additional rules for patients who completed Pfizer 2-dose series, Moderna 2-dose series, Janssen 1-dose series, Pfizer COVID-19 Child (5-17) 2-dose series, COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine.
- Added additional support and logic in ICE to handle the following:
- This release includes an important security update. We strongly recommend that users update to this release as soon as possible.
...
- This release includes the following COVID-19 updates:
- Added additional support and logic in ICE to handle the following:
- COVID-19 Pfizer Pediatric Dose (5 through 11 years old)
- Evaluation of Janssen booster dose as Valid
- Added COVAXIN (CVX 502) as a WHO-approved vaccine for EUA
- An updated Implementation Guide with the following new codes:
- CVX 218 - vaccine code for the COVID-19 Pfizer pediatric vaccine
- BOOSTER_DOSE - new recommendation reason code to indicate that the recommendation is for a booster dose.
- Added additional support and logic in ICE to handle the following:
- Note about upcoming ICE release (scheduled for December 2021)
- As always, HLN is actively monitoring all news and updates in regards to new and existing COVID-19 vaccines. Currently, we are working on adding additional support and logic (based on latest published guidance) in ICE to handle the following:
- Updates to Booster Dose rules
- Updates to Additional Dose rules
- Updated Absolute Minimum Intervals and Absolute Minimum Ages
- As always, HLN is actively monitoring all news and updates in regards to new and existing COVID-19 vaccines. Currently, we are working on adding additional support and logic (based on latest published guidance) in ICE to handle the following:
...
- This release includes the following COVID-19 updates:
- Added additional support and logic in ICE to handle the following:
- COVID-19 Booster Dose for Pfizer Vaccine
- Performance Improvement:
- On service start up, if the km.threads property configuration value is increased, ICE no longer requires additional memory to establish the increased number of threads.
- Added additional support and logic in ICE to handle the following:
- Note about upcoming ICE release (tentatively scheduled for mid-November 2021)
- As always, HLN is actively monitoring all news and updates in regards to new and existing COVID-19 vaccines. Currently, we are working on adding additional support and logic (based on latest published guidance) in ICE to handle the following:
- COVID-19 Booster Dose for Moderna and Janssen Vaccines
- As always, HLN is actively monitoring all news and updates in regards to new and existing COVID-19 vaccines. Currently, we are working on adding additional support and logic (based on latest published guidance) in ICE to handle the following:
...
- This release includes the following COVID-19 updates:
- Added additional support and logic in ICE to handle the following:
- COVID-19 Additional Dose - a dose administered when the immune response to a standard primary vaccine series is likely not to be protective.
- Note - Alternatively, a “booster” dose of vaccine is a dose administered to restore protection after the effectiveness of protection from the primary series has declined. Once FDA approval is granted and ACIP recommendations are published in regards to "booster" doses, ICE will be updated accordingly; updates will likely be included in the next release of ICE.
- COVID-19 Vaccines Not Authorized by FDA, but Authorized by WHO
- Note - The previous version of ICE, Version 1.29.1 supports the handling of one COVID-19 vaccine that falls under this category - AstraZeneca COVID-19 vaccine (CVX 210).
- COVID-19 Vaccines Not Authorized by the FDA or WHO
- COVID-19 Vaccines Not Authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine
- COVID-19 Additional Dose - a dose administered when the immune response to a standard primary vaccine series is likely not to be protective.
- Added additional support and logic in ICE to handle the following:
...
- This release includes the following COVID-19 updates:
- Updates have been made to expand age ranges down to >=12 years old for the Pfizer COVID-19 Vaccine (CVX 208).
- For patients with no prior doses of COVID-19 vaccine, updated recommendations to recommend COVID-19 to patients >= 12 years old.
- Note - ICE previously had a conditional recommendation for patients with no prior doses of COVID-19 vaccine.
- Support has been added to handle AstraZeneca COVID-19 vaccine (CVX 210) shots reported on the patient record.
- As of now, the AstraZeneca COVID-19 vaccine has not yet been FDA approved in the U.S. , but is approved by the WHO. See COVID-19 Vaccine Group - Prior to September 12, 2023 page for details.
- When the FDA approves the AstraZeneca COVID-19 vaccine (CVX 210) for use in the U.S., ICE will be updated as necessary.
- As of now, the AstraZeneca COVID-19 vaccine has not yet been FDA approved in the U.S. , but is approved by the WHO. See COVID-19 Vaccine Group - Prior to September 12, 2023 page for details.
- In addition to the above updates, added evaluation reason code VACCINE_NOT_APPROVED_IN_US to the ICE Implementation Guide.
- Note: This is implementation of COVID-19 Vaccine Group in ICE based on interim recommendations from ACIP. As additional guidelines from ACIP are published and/or vaccines become available, the COVID-19 logic in ICE will be updated.
...
- This is implementation of COVID-19 Vaccine Group in ICE based on interim recommendations from ACIP. As additional guidelines from ACIP are published and/or vaccines become available, the COVID-19 logic in ICE will be updated.
- This release includes support for the Pfizer COVID-19 vaccine (CVX 208), Moderna COVID-19 vaccine (CVX 207), and COVID-19, Unspecified Formulation (CVX 213).
- In addition to the above CVX codes, added recommendation reason code BASED_ON_VAC_AVAIL_AND_PRIORITY_RECS to the ICE Implementation Guide.
- The updated ICE Implementation Guide documents these codes. A version of this same guide with the changes since 1.24.1 highlighted and a Google Sheet with the same ICE codes are also available as an added convenience.
...
- Updated Pneumococcal rules as per the June 2019 ACIP Vote:
- PCV13 vaccination is no longer routinely recommended for all adults aged ≥65 years. Instead, shared clinical decision-making for PCV13 use is recommended for persons aged ≥65 years who do not have an immunocompromised condition, CSF leak, or cochlear implant and who have not previously received PCV13.
- ACIP continues to recommend that all adults aged ≥65 years receive 1 dose of PPSV23. A single dose of PPSV23 is recommended for routine use among all adults aged ≥65 years.
- Reference MMWR, November 22, 2019, Vol. 68, No. 46 for additional information.
...
- Updated HPV rules as per the June 2019 ACIP Vote:
- Harmonized recommendation for catch-up vaccination for males and females through age 26 years who are not adequately vaccinated.
- Recommends vaccination based on shared clinical decision making for individuals aged 27 through 45 years who are not adequately vaccinated.
General Update
- A duplicate shot/same day fix whereby, in certain circumstances, a non-combination shot might be selected instead of the combination shot.
- Slight change to the way the dose number included in the vMR output is determined. The dose number represents the targeted number of the dose in the series, whether the dose is valid or invalid (so, for instance, both a "valid" second dose following an invalid second dose will have dose number 2 indicated). However, if the patient has passed the eligible last date for a particular dose (e.g., Hib, Pneumococcal) and receives a subsequent dose, the dose number of that subsequent dose will indicate the count of actual doses received and will not consider the earlier dose that was missed which cannot now be administered.
8/28/2019: Release v1.20.1
...
- Updated the DTP Adolescent Tdap Recommendation and Evaluation rules as per the new Tdap guidance included in the 2019 CDC Immunization Schedule
- Added a DTP 3-dose series exception rule requiring that in order for a primary series to be complete via the DTP 3-dose series, at least one of the doses given must be a pertussis-containing dose
5/31/2019: Release v1.17.1
HPV Update
- Updates to HPV 3-dose series to align with CDSi
- Updated Recommended Interval between Dose 1 and 2 from 1 month to 4 weeks
- Updated Absolute Minimum Interval between Dose 1 and 3 from 112 days to 5 months - 4 days
DTP Update
- Updated the DTP 3-dose series Absolute Minimum Interval between Dose 2 and 3 from 164 days to 6 months - 4 days to align with CDSi.
- Updated Adolescent Tdap Exception A Rule to "The patient DOES NOT have a dose of pertussis vaccine at >= 4 years - 4 days."
Zoster Update
- Added rule "Recommended Interval After Adult Varicella (CVX 21) Doses"
- If patient is administered adult varicella (CVX 21) doses, the minimum interval and recommended interval between the adult varicella (CVX 21) doses to Zoster is 8 weeks.
- Example:
- Varicella (CVX 21) at 50 years, 1 month.
- Varicella (CVX 21) at 50 years, 3 months.
- Recommend Zoster (CVX 187) at Varicella Dose 2 + recommended interval (8 weeks)
...
General - Same Day Shots Update
- Updated and improved the handling of shots administered on the same day.
3/7/2019: Release v1.16.1
...
- Please refer to the March 7 News entry for general information and suggestions related to this release.
Pneumococcal Update
- Updated recommendation rule to distinguish between patients >=5 years old who have completed the childhood Pneumococcal series and patients who have not. The updated rule states:
- "If a patient is >= 5 years (or will be >= 5 years at the recommended due date) and < 65 years, and they have completed the Child Series, then the Recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK; otherwise the Recommendation is Conditional and the reason code is HIGH_RISK."
- "If a patient is >= 5 years (or will be >= 5 years at the recommended due date) and < 65 years, and they have completed the Child Series, then the Recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK; otherwise the Recommendation is Conditional and the reason code is HIGH_RISK."
Polio Update
- Updated Series complete with 3-doses rule to include the minimum interval = 6 months and absolute minimum interval = 6 months - 4 days.
...
Shots Administered "before" the Patient's DOB
- Improved handling of shots marked as administered before the patient's date of birth.
Overdue Date/Earliest Date
...